Key result
A 44-year-old female developed a 5 cm pericardial effusion and cardiac tamponade requiring emergency pericardiocentesis after receiving the Pfizer-BioNTech COVID-19 vaccine.
Case Report (n=1)
No
This case report highlights a rare occurrence of pericardial effusion and cardiac tamponade following administration of the Pfizer-BioNTech COVID-19 vaccine, emphasizing the need for clinical awareness.
Answers are grounded in this paper and cite their sources.
Rare post-vaccine tamponade warrants clinical awareness; leaves open causality in this isolated case report.
A 44-year-old female patient with no known history of chronic disease was admitted to the emergency room with tachycardia and shortness of breath after covid-19 vaccine (Pfizer Biontech). The blood pressure of the patient who was consulted to cardiology: 80/40 mmHg. Echocardiography (ECHO): Ejection Fraction was 65%, pericardial effusion (PE) was present at its widest point, 5 cm encircling the heart, collapsing the right heart cavities in diastole, forming the clinic of tamponade. Emergency pericardiocentesis was applied to the patient. Pericardial fluid content of the patient was serous. The patient, whose clinical stability was stabilized after pericardiocentesis, was followed in the coronary intensive care unit. No pericardial effusion was observed in the control echo duringfollow-up. Thepatient's PCR results were negative. The patient was discharged with cardiology outpatient control.
No takes yet. Share an insight, caveat, or question.
Karakayalı et al. (2021) conducted a case report in Pericardial effusion and cardiac tamponade (n=1). Pfizer-BioNTech COVID-19 vaccine was evaluated on Development of pericardial effusion and cardiac tamponade. A 44-year-old female developed a 5 cm pericardial effusion and cardiac tamponade requiring emergency pericardiocentesis after receiving the Pfizer-BioNTech COVID-19 vaccine.
Synapse has enriched 10 related papers. Consider them for comparative context: